For anyone - like myself - who was on Tysabri at its inception and had to go off when it was pulled from the market, you should know that an article just appeared in the Annals of Neurology with this conclusion:
"In this cohort of patients with MS who had disease refractive to multiple therapeutics before starting natalizumab treatment, magnetic resonance imaging and clinical disease activity returned, often aggressively, following discontinuation of natalizumab therapy. These findings suggest we should consider strategies to minimize the risk of immune reconstitution inflammatory syndrome after natalizumab discontinuation."
In a larger sense, it may warrant a deeper conversation with your neuro if you want to either start Tysabri or take a break from it.
Todd
"In this cohort of patients with MS who had disease refractive to multiple therapeutics before starting natalizumab treatment, magnetic resonance imaging and clinical disease activity returned, often aggressively, following discontinuation of natalizumab therapy. These findings suggest we should consider strategies to minimize the risk of immune reconstitution inflammatory syndrome after natalizumab discontinuation."
In a larger sense, it may warrant a deeper conversation with your neuro if you want to either start Tysabri or take a break from it.
Todd
Comment